Oral Carnitine in Heart Failure Patients
Key facts
- Where
- London, CanadaSee the site
- Phase
- Early phase 1
Where in Canada
- London Health Sciences CentreLondon, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Trial code
- NCT07201714
- Record updated
- 20 April 2026
- Original description
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.Read full original descriptionShow less
Oral L-Carnitine Supplementation in Cardiorenal Heart Failure Patients
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.
Inclusion: Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome; Stage 1, 2, 3a, 3b, or 4 chronic kidney disease; Age ≥ 18 years; Able to speak and read English; Willing and able to provide consent.
Exclusion: Currently undergoing renal replacement therapy of any kind; History of seizures of any type; Estimated GFR <15 mL/min/1.73m2 or Stage 5 chronic kidney disease; Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone; Pregnant, breastfeeding or intending pregnancy; Unable to provide consent.